[go: up one dir, main page]

AR110922A1 - Compuestos inhibidores del vih - Google Patents

Compuestos inhibidores del vih

Info

Publication number
AR110922A1
AR110922A1 ARP180100247A ARP180100247A AR110922A1 AR 110922 A1 AR110922 A1 AR 110922A1 AR P180100247 A ARP180100247 A AR P180100247A AR P180100247 A ARP180100247 A AR P180100247A AR 110922 A1 AR110922 A1 AR 110922A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
optionally substituted
membered heterocyclyl
heteroatoms selected
Prior art date
Application number
ARP180100247A
Other languages
English (en)
Inventor
Zheng Yang
- Trejo Martin Teresa Alejandra Yu
Nathan Shapiro
John O Link
Darryl Kato
Ashley Anne Katana
Jeromy J Cottell
Elbert Chin
Elizabeth M Bacon
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61244746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR110922(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR110922A1 publication Critical patent/AR110922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ es un heterociclo de 5 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados entre N, O y S, o un heteroarilo de 5 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados entre N, O y S, donde el heterociclo de 5 a 10 miembros o heteroarilo de 5 a 10 miembros está opcionalmente sustituido con 1 a 5 grupos Rᵃ; R² y R³ son cada uno independientemente alquilo C₁₋₄, cicloalquilo C₃₋₆, O-R²A, alquilo C₁₋₂-O-R²A, N-(R³A)₂, o alquilo C₁₋₂-N-(R³A)₂, donde cada R²A es independientemente alquilo C₁₋₄, cicloalquilo C₃₋₆, o un heterociclilo de 4 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados de N, O y S, donde cada R³A es independientemente hidrógeno, alquilo C₁₋₄, cicloalquilo C₃₋₆, o COO(Rᵉ), y donde cada cicloalquilo C₃₋₆ o heterociclilo de 4 a 10 miembros está opcionalmente sustituido por 1 a 3 grupos Rᶠ, donde cada Rᶠ es independientemente alquilo C₁₋₂ o halógeno; R⁴ es hidrógeno, halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, o haloalcoxi C₁₋₄; R⁷ es hidrógeno, halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, o haloalcoxi C₁₋₄; R⁵, R⁶, R⁸, y R⁹ son cada uno independientemente hidrógeno, halo, alquilo C₁₋₂, haloalquilo C₁₋₂, o cicloalquilo C₃₋₆; y donde dos o más R⁴, R⁵ y R⁶ o dos o más R⁷, R⁸, y R⁹ opcionalmente se unen para formar uno o más grupos cicloalquilo C₃₋₆ que están opcionalmente sustituidos con 1 a 4 grupos seleccionados de halógeno, alquilo C₁₋₂, y haloalquilo C₁₋₂; cada R¹⁰ es independientemente halógeno, ciano, alcoxi C₁₋₄, alquilo C₁₋₆, o cicloalquilo C₃₋₆; n es 0 a 4; cada Rᵃ es independientemente halógeno, alquilo C₁₋₄, alquilo C₁₋₄ con 1 a 2 grupos seleccionados de hidroxilo y alcoxi C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, cicloalquilo C₃₋₆, heterociclilo de 4 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados de N, O y S que está opcionalmente sustituido con Rᵃ¹, o O-R³B, donde R³B es cicloalquilo C₃₋₆ opcionalmente sustituido con Rᵃ¹ o un heterociclilo de 4 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados de N, O y S opcionalmente sustituido con Rᵃ¹, donde cada Rᵃ¹ es independientemente alquilo C₁₋₄, cicloalquilo C₃₋₆, haloalquilo C₁₋₄, o heterociclilo de 4 a 8 miembros que tiene 1 a 3 heteroátomos seleccionados entre N, O y S; A es etinilo o un enlace; X¹ es un arilo de 6 a 10 miembros o un heteroarilo de 5 a 10 miembros que tiene de 1 a 3 heteroátomos seleccionados entre N, O y S, donde cada arilo de 6 a 10 miembros o heteroarilo de 5 a 10 miembros está opcionalmente sustituido con 1 a 4 grupos Rᵇ; X² es hidrógeno o un heterociclilo de 4 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados de N, O y S, donde el heterociclilo de 4 a 10 miembros está opcionalmente sustituido con un R¹¹ y opcionalmente sustituido con 1 a 5 grupos Rᵇ; R¹¹ es C=O(Rᶜ), CH₂(Rᵈ), S(O)₁₋₂(alquilo C₁₋₄), S(O)₁₋₂-cicloalquilo C₃₋₆, un heterociclilo de 4 a 10 miembros que tiene de 1 a 5 heteroátomos seleccionados de N, O y S, o un heteroarilo de 5 a 9 miembros que tiene de 1 a 5 heteroátomos seleccionados de N, O y S, donde cada heterociclilo de 4 a 10 miembros o heteroarilo de 5 a 9 miembros está opcionalmente sustituido con 1 a 5 grupos Rᵇ; cada Rᵇ es independientemente halógeno, oxo, alquilo C₁₋₄, alquilo C₁₋₄ con 1 a 2 grupos seleccionados de hidroxilo y alcoxi C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, o COO(Rᵉ); Rᶜ es alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, N(Rᵉ)₂, cicloalquilo C₃₋₆, o un heterociclilo de 4 a 6 miembros que tiene de 1 a 3 heteroátomo seleccionados de N, O, y S, donde el cicloalquilo C₃₋₆ y el heterociclilo de 4 a 6 miembros están opcionalmente sustituidos por 1 a 5 grupos Rᵇ; Rᵈ es COO(Rᵉ), N(Rᵉ)₂, cicloalquilo C₃₋₆, o un heterociclilo de 4 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados de N, O, y S, donde el cicloalquilo C₃₋₆ y el heterociclilo de 4 a 6 miembros está opcionalmente sustituido por 1 a 5 grupos Rᵇ; cada R¹² es alquilo C₁₋₂, halo, -O-alquilo C₁₋₂, o ciano; cada p es 0 a 4; y cada Rᵉ es independientemente hidrógeno o alquilo C₁₋₄.
ARP180100247A 2017-02-06 2018-02-02 Compuestos inhibidores del vih AR110922A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762455348P 2017-02-06 2017-02-06

Publications (1)

Publication Number Publication Date
AR110922A1 true AR110922A1 (es) 2019-05-15

Family

ID=61244746

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100247A AR110922A1 (es) 2017-02-06 2018-02-02 Compuestos inhibidores del vih

Country Status (34)

Country Link
US (5) US10294234B2 (es)
EP (2) EP3909949A1 (es)
JP (4) JP6814304B2 (es)
KR (4) KR102547909B1 (es)
CN (3) CN115991708A (es)
AR (1) AR110922A1 (es)
AU (3) AU2018215546B2 (es)
CA (1) CA3051588C (es)
CL (1) CL2019002204A1 (es)
CO (1) CO2019008531A2 (es)
CR (1) CR20190354A (es)
CY (1) CY1124276T1 (es)
DK (1) DK3577110T3 (es)
DO (1) DOP2019000201A (es)
EA (1) EA201991684A1 (es)
ES (1) ES2877595T3 (es)
HR (1) HRP20210732T1 (es)
HU (1) HUE054690T2 (es)
IL (1) IL268282B2 (es)
JO (1) JOP20180009A1 (es)
LT (1) LT3577110T (es)
MX (2) MX2019009212A (es)
MY (1) MY200608A (es)
PE (1) PE20191260A1 (es)
PH (1) PH12019501786A1 (es)
PL (1) PL3577110T3 (es)
PT (1) PT3577110T (es)
SA (1) SA519402405B1 (es)
SG (1) SG11201907058TA (es)
SI (1) SI3577110T1 (es)
TW (3) TWI854464B (es)
UA (1) UA123298C2 (es)
UY (1) UY37592A (es)
WO (1) WO2018145021A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
KR102180740B1 (ko) 2016-08-19 2020-11-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TW202024061A (zh) * 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CN116854630A (zh) 2018-02-16 2023-10-10 吉利德科学公司 用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TWI766172B (zh) * 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4065116A1 (en) * 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
AU2021296607B2 (en) 2020-06-25 2024-07-25 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021377614A1 (en) 2020-11-11 2023-06-22 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US11890297B2 (en) 2021-01-25 2024-02-06 Brii Biosciences, Inc. Combination therapy for HIV with adenosine derivative and capsid inhibitors
KR20240113577A (ko) 2021-12-03 2024-07-22 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024220624A1 (en) 2023-04-19 2024-10-24 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2847064A1 (de) * 1978-10-28 1980-05-08 Boehringer Mannheim Gmbh Verwendung von 2-cyanaziridinen als therapeutica bei strahlenschaeden
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE59207226D1 (de) 1991-07-03 1996-10-31 Ciba Geigy Ag Pharmakologisch wirksame Hydrazinderivate und Verfahren zu deren Herstellung
US5753652A (en) 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
AU2003200066B9 (en) 1992-03-11 2007-02-15 Narhex Limited Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons
JPH07504654A (ja) 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
EP0639184A1 (en) 1992-05-07 1995-02-22 Merck & Co. Inc. New quinazolines as inhibitors of hiv reverse transcriptase
EP0604368B1 (de) 1992-12-23 1996-09-18 Ciba-Geigy Ag Antiretrovirale hydrazinderivate
US5461067A (en) 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
CA2237016A1 (en) 1995-11-21 1997-05-29 Novartis Ag Azahexane derivatives as substrate isosters of retroviral asparate proteases
TW409125B (en) 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
ATE213725T1 (de) 1996-07-17 2002-03-15 Novartis Ag Anilinopeptid-derivate
CH694251A5 (de) 1999-07-14 2004-10-15 Eprova Ag Herstellung von Tetrahydropterin und Derivaten.
EP1244610B1 (en) 1999-12-23 2008-07-16 Ampac Fine Chemicals LLC Improved preparation of 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
CA2448084A1 (en) 2001-05-22 2002-11-28 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
EP1392315A1 (en) 2001-06-08 2004-03-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease
BR0212242A (pt) 2001-08-28 2004-07-20 Upjohn Co Métodos para tratar ou previnir mal de alzheimer e uma doença, tratar mal de alzheimer e um indivìduo que tem ou para evitar que um paciente adquira uma doença ou condição, para inibir a atividade de beta-secretase, a clivagem de um isotipo de proteìna de precursor de amilóide e a produção de peptìdeo beta amilóide em uma célula e de placa beta-amilóide em um animal, para produzir um complexo beta-secretase, composição e uso de um composto
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US20050131017A1 (en) * 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
WO2005061487A1 (en) 2003-12-11 2005-07-07 Abbott Laboratories Hiv protease inhibiting compounds
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
EP1737881B1 (en) 2004-02-27 2009-06-24 Schering Corporation Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
MXPA06015108A (es) 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
PL1851193T3 (pl) * 2005-02-10 2009-09-30 Medivir Ab Inhibitory proteazy HIV
WO2007002172A2 (en) 2005-06-22 2007-01-04 University Of Massachusetts Hiv-1 protease inhibitors
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
NZ573888A (en) * 2006-07-21 2012-02-24 Gilead Sciences Inc Aza-peptide protease inhibitors
US7723380B2 (en) * 2006-07-21 2010-05-25 Gilead Sciences, Inc. Antiviral protease inhibitors
WO2008111116A1 (ja) 2007-03-09 2008-09-18 Pioneer Corporation Ａｖ複合編集装置、ａｖ処理装置およびプログラム
CN101702908A (zh) 2007-03-23 2010-05-05 麻萨诸塞州大学 Hiv-1蛋白酶抑制剂
EP2322509B1 (en) 2007-06-12 2012-08-22 Concert Pharmaceuticals Inc. Azapeptide derivatives as HIV protease inhibitors
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
AU2008323558C1 (en) 2007-11-16 2014-05-01 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20110178305A1 (en) 2008-05-08 2011-07-21 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TWI466735B (zh) 2008-09-18 2015-01-01 Gs Yuasa Int Ltd 紫外線照射裝置
TWI432436B (zh) 2008-12-09 2014-04-01 Gilead Sciences Inc 類鐸受體的調節劑
US20120041019A1 (en) 2008-12-17 2012-02-16 Mutz Mitchell W Protease inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
SG178115A1 (en) 2009-07-29 2012-03-29 Schering Corp ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF ß-AMINO-a- HYDROXY AMIDES
EP2292589A1 (en) 2009-09-02 2011-03-09 IMTM GmbH Novel multifunctional peptidase inhibitors, especially for medical use
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
CN102190638A (zh) * 2010-03-16 2011-09-21 中国科学院上海药物研究所 联芳基醇二胺类化合物、其药物组合物、制备方法及应用
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
PT2588450T (pt) 2010-07-02 2017-08-03 Gilead Sciences Inc Derivados do ácido naft-2-ilacético para tratamento da sida
UY33479A (es) 2010-07-02 2012-01-31 Gilead Sciences Inc Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
CA2810005A1 (en) 2010-09-02 2012-03-08 Purdue Research Foundation Fused tricyclic ether carbamates and their use
WO2012092188A1 (en) 2010-12-27 2012-07-05 Ghosh Arun K Hydrogen bond forming p1 ligands and methods for treating hiv
WO2012092168A1 (en) 2010-12-27 2012-07-05 Purdue Research Foundation Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
WO2012170792A1 (en) 2011-06-10 2012-12-13 Concert Pharmaceuticals, Inc. Atazanavir metabolite derivatives
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
US9341365B2 (en) 2012-01-12 2016-05-17 Daniel L. Gan Eversible candle holder
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
AU2013366981A1 (en) 2012-12-27 2015-06-18 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014127052A1 (en) * 2013-02-13 2014-08-21 Zondlo Neal Perfluoro-tert-butyl hydroxyproline
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015097667A2 (en) 2013-12-23 2015-07-02 Cellworks Group, Inc., A composition, process of preparation of said composition, kit and a method of treating cancer
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015175704A1 (en) * 2014-05-14 2015-11-19 The Regents Of The University Of California Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
US9670225B2 (en) 2014-05-16 2017-06-06 Purdue Research Foundation HIV-1 protease inhibitors and uses thereof
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
JP2018513183A (ja) 2015-04-23 2018-05-24 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
KR20180004811A (ko) 2015-05-15 2018-01-12 길리애드 사이언시즈, 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서의 활성을 갖는 벤즈이미다졸 및 이미다조피리딘 카르복스이미드아미드 화합물
EP3515897B1 (en) * 2016-09-19 2021-08-18 H. Lundbeck A/S Piperazine carbamates as modulators of magl and/or abhd6 and their use
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物

Also Published As

Publication number Publication date
TW201840555A (zh) 2018-11-16
PL3577110T3 (pl) 2021-10-25
JOP20180009A1 (ar) 2019-01-30
CN110536889B (zh) 2022-12-16
EP3577110B1 (en) 2021-04-21
EP3577110A1 (en) 2019-12-11
UY37592A (es) 2018-08-31
TWI794629B (zh) 2023-03-01
AU2020264300B2 (en) 2022-08-25
US20250042910A1 (en) 2025-02-06
HRP20210732T1 (hr) 2021-09-17
CN115093421A (zh) 2022-09-23
US20230027055A1 (en) 2023-01-26
US11078208B1 (en) 2021-08-03
SI3577110T1 (sl) 2021-08-31
WO2018145021A1 (en) 2018-08-09
AU2018215546A1 (en) 2019-08-22
KR102547909B1 (ko) 2023-06-28
LT3577110T (lt) 2021-07-12
IL268282B (en) 2022-10-01
CA3051588A1 (en) 2018-08-09
BR102018002152A8 (pt) 2022-11-16
JP2020506941A (ja) 2020-03-05
KR102749565B1 (ko) 2025-01-03
JP7282112B2 (ja) 2023-05-26
AU2022271510A1 (en) 2023-01-05
US20190308983A1 (en) 2019-10-10
TWI854464B (zh) 2024-09-01
KR102430812B1 (ko) 2022-08-11
MX2019009212A (es) 2019-09-27
KR20230097222A (ko) 2023-06-30
CL2019002204A1 (es) 2019-12-20
CY1124276T1 (el) 2022-07-22
CN115991708A (zh) 2023-04-21
IL268282B2 (en) 2023-02-01
US10294234B2 (en) 2019-05-21
AU2018215546B2 (en) 2020-08-13
MX2022012616A (es) 2022-11-07
JP7105853B2 (ja) 2022-07-25
BR102018002152A2 (pt) 2018-10-30
TWI701243B (zh) 2020-08-11
KR20250008988A (ko) 2025-01-16
AU2020264300A1 (en) 2020-12-03
KR20190115458A (ko) 2019-10-11
PH12019501786A1 (en) 2020-06-29
NZ755929A (en) 2021-08-27
PE20191260A1 (es) 2019-09-18
CR20190354A (es) 2019-09-19
US12084455B2 (en) 2024-09-10
ES2877595T3 (es) 2021-11-17
MY200608A (en) 2024-01-05
CO2019008531A2 (es) 2019-10-31
DK3577110T3 (da) 2021-06-14
US20180258097A1 (en) 2018-09-13
SG11201907058TA (en) 2019-08-27
PT3577110T (pt) 2021-06-17
JP2022172294A (ja) 2022-11-15
IL268282A (en) 2019-09-26
SA519402405B1 (ar) 2024-03-03
DOP2019000201A (es) 2019-08-30
TW202344506A (zh) 2023-11-16
EP3909949A1 (en) 2021-11-17
KR20220116340A (ko) 2022-08-22
JP2021073287A (ja) 2021-05-13
CA3051588C (en) 2022-08-23
JP2021046422A (ja) 2021-03-25
JP6814304B2 (ja) 2021-01-13
TW202043219A (zh) 2020-12-01
UA123298C2 (uk) 2021-03-10
HUE054690T2 (hu) 2021-09-28
EA201991684A1 (ru) 2020-02-11
CN110536889A (zh) 2019-12-03
US10752636B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
AR110922A1 (es) Compuestos inhibidores del vih
AR117616A1 (es) Compuestos anti-vih
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR103252A1 (es) Compuestos de quinazolina
AR114950A1 (es) Compuestos de benzamida
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR100058A1 (es) DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg
AR110405A1 (es) Compuestos
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR105875A1 (es) Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
AR099788A1 (es) Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR107840A1 (es) INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR102222A1 (es) Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR099933A1 (es) Derivados heterocíclicos de piridina agonistas de cb2
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR107570A1 (es) Compuestos químicos